PPT-Phase II studies of Nivolumab

in patients with Advanced Squamous SQ or Non Squamous NSQ NonSmall Cell Lung Cancer NSCLC Intervista a Lucio Crinò Background Programmed death 1 PD1 is an immune checkpoint that suppresses antitumor immunity Nivolumab ONO4538 BMS936558 a fully human IgG4 antiPD1 antibody has shown durable clinical activity in previous phase I and II trials in several tumor types In March 2015 US Food and Drug Administration FDA has approved Nivolumab injection for the treatment of patients with metastatic squamous SQ nonsmall cell lung cancer NSCLC with progression on or after platinumbased chemotherapy Here we report the results of two phase II studies to evaluate the efficacy and safety of nivolumab in previously treated advanced SQ JapicCTINo132072 and NSQ JapicCTINo132073 NSCLC pts in Japan . the Spectrum of Lung Cancer. Karen Kelly, MD. Professor of Medicine. Associate Director for Clinical Research. Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon. Endowed Chair in Cancer Clinical Research. the Spectrum of Lung Cancer. Karen Kelly, MD. Professor of Medicine. Associate Director for Clinical Research. Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon. Endowed Chair in Cancer Clinical Research. nivolumab. Expanded Access . Programme. (EAP): preliminary data from a real-world population. Lucio . Crinò. et al.. Intervista a Angelo . Delmonte. Background:. Nivolumab is the first checkpoint inhibitor approved for the treatment of squamous non small cell lung cancer (Sq-NSCLC) to show a survival benefit in a randomised phase III trial. The experience of patients and physicians in routine clinical practice is often different from those in a controlled clinical trial setting. The purpose of this analysis is to evaluate nivolumab use in real world setting. . Phase I experience. Matteo Carlino. Crown Princess Mary Cancer Centre Westmead and . Blacktown. Hospitals. Melanoma . Institute . Australia. The University of Sydney. .. The Westmead and MIA. Phase I experience. F.A.C.P. .. Head, Immunotherapy Section. Chief, Genitourinary Malignancies Branch . & Director, Medical Oncology Service. Center. for Cancer Research. National Cancer Institute, NIH . NIH Building 10: Immunotherapy & Prostate Cancer. Program Goals. Incidence of RCC in the United States. Survival. Current Treatment. Toxicities to Treatment. IL-2: Function. Challenges in Clinical Outcome With Targeted Drugs. Nivolumab. Mechanism of Action. May 22, 2013. 2.  . Evaluating Uncertainty . Feedback from stakeholders and the Independent Scientific Panel (ISP) stressed that the understanding and evaluation of uncertainty is important in the prioritization. Expanding Treatment Options in SCCHN: What Role Do Cancer Immunotherapies Have? Moderator Robert Haddad, MD Associate Professor of Medicine Harvard Medical School Disease Center Leader Head and Neck Oncology Program proceedings from the live CME event and may include . the use of trade names and other raw, unedited content. . Breakfast with the Investigators . Management of Melanoma. Monday, June 3, 2019 . 6:45 AM – 7:45 AM. actual. . video-recorded proceedings from the . live . CME event and may include the use of trade names and other raw, unedited content. . Consensus OR Controversy? . Clinical Investigators Provide Perspectives on the Treatment of Metastatic Non-Small Cell Lung Cancer in Patients Without Targetable Tumor Mutations . ADULT Updated: October 2 8 , 20 20 eria for Use Page 1 of 3 Regimen Reference Order – CUTA – nivolumab + ipilimumab ARIA: CUTA - [nivolumab + ipilimumab (Phase 1) ] CUTA - [nivolumab q 14 da ADULTUpdated November 122019Page 1of 2Regimen Reference OrderCUTA nivolumabAdjuvantARIA CUTA nivolumabq 14 daysADJCUTA nivolumab q 28 daysADJPlanned Course Every 14 days for one year26 cycles totalOR Jeff Moscow, M.D. Investigational Drug Branch, CTEP/DCTD/NCI. EDDOP: A P30 supplement program for NCI-CCs NOT in the ETCTN UM1 program. NCI CCs that are not affiliated with the CTEP ETCTN UM1 program could apply for administrative supplements in the . vs . Platinum-Doublet Chemotherapy . as First-line Treatment for . Advanced . Non-Small . Cell Lung . Cancer: Initial . Results . From . CheckMate 227. Matthew D. Hellmann,. 1. . Tudor-. Eliade. . Ciuleanu,.